Metsera Revenue and Competitors

USA

Location

#882

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Metsera's estimated annual revenue is currently $15.7M per year.(i)
  • Metsera's estimated revenue per employee is $155,000

Employee Data

  • Metsera has 101 Employees.(i)
  • Metsera grew their employee count by 173% last year.

Metsera's People

NameTitleEmail/Phone
1
Executive Administrator to the CEOReveal Email/Phone
2
CEOReveal Email/Phone
3
Founder & Executive ChairmanReveal Email/Phone
4
EVP Research & Development, Founder and Executive Chairman, ZihippReveal Email/Phone
5
CEOReveal Email/Phone
6
Chief Development OfficerReveal Email/Phone
7
Chief Design OfficerReveal Email/Phone
8
Chief Design OfficerReveal Email/Phone
9
Chief Medical OfficerReveal Email/Phone
10
Chief Scientific OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$99.4M45840%N/AN/A
#2
$20.6M13322%N/AN/A
#3
$156.1M146-70%$145MN/A
#4
$3.5M45-25%$150MN/A
#5
$1.6M210%$459.5MN/A
#6
$67.3M31016%$180.7MN/A
#7
$8.5M55-2%N/AN/A
#8
$256.3M10259%$168.5MN/A
#9
$9.1M59-9%N/AN/A
#10
$16.6M1073%N/AN/A
Add Company

What Is Metsera?

Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Founded in 2022 by Population Health Partners and ARCH Venture Partners, Metsera has raised $290 million in financing from leading healthcare investors and is based in New York City.

keywords:N/A

N/A

Total Funding

101

Number of Employees

$15.7M

Revenue (est)

173%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$27.3M10125%N/A
#2
$17.6M10119%N/A
#3
$29.3M1016%N/A
#4
$27.3M10115%N/A
#5
$33.3M10112%N/A